ABSTRACT
Psoriatic Spectrum Diseases (PSD) affect over 8 million individuals in the U.S. living with psoriasis (PsO) or
psoriatic arthritis (PsA) and encompass heterogeneous phenotypes of disease, ranging from plaque, guttate,
palmoplantar, inverse, pustular, and erythrodermic forms of psoriasis, to synovial, enthesial, and axial forms of
PsA. Here, we assembled a world class multidisciplinary team of scientists in PSD cohort assembly, clinical
phenotyping, biosample acquisition, pathology, statistics, and bioinformatics, for the Accelerating Medicines
Partnership Autoimmune and Immune-Mediated Diseases (AMP AIM) PSD Disease Teams (DTs).
The major scientific goals of the PSD DT are to understand the cellular and molecular composition of distinct
PSD endotypes and how they link with phenotypes, to identify how key pathogenic or regulatory cells spatially
interact with each other and with environmental cues (i.e., microbiome), and to define at a single-cell level how
the transition to PsA unfolds in the setting of PsO. To accomplish the goals of the PSD AMP, we propose the
creation of the ELLIPSS (ELucidating the Landscape of Immunoendotypes in Psoriatic Skin and Synovium)
Disease Team (DT). The AIMS of the ELLIPSS Team are to 1) to enroll diverse PSD cohorts and perform clinical
phenotyping, data capture, and tissue collection. 2) to implement an effective management plan for the ELLIPSS
multidisciplinary team. 3) to optimize interface of ELLIPSS team with AMP-AIM network. Lastly, a robust
Opportunities Fund (OF) management program is proposed under the direction and leadership of Dr. James T.
Elder at University of Michigan.
The ELLIPSS PSD DT will efficiently integrate with the AMP AIM Network, facilitate collection of PSD biosamples,
and help provide an unprecedented view of cell types and states, along with spatial and tissue interactions (skin,
joint, blood, microbiome) to deconstruct/reconstruct the psoriatic disease spectrum.
